Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | INMT | O95050 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16234595 | 0.84 | CYP1A2 (0.31) | CYP2D6 | |
| SCHEMBL16233129 | 0.83 | HRH4 (0.33) | HRH4HRH2HRH3 | |
| SCHEMBL16233118 | 0.81 | — | — | |
| SCHEMBL251940 | 0.81 | CYP2D6 (0.42) | USP2INMTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23075888 | 0.80 | USP2 (0.35) | USP2INMTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22106057 | 0.80 | USP2 (0.35) | USP2INMTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL16233143 | 0.80 | — | — | |
| SCHEMBL22106056 | 0.79 | ALDH1A1 (0.36) | USP2INMTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL22106055 | 0.79 | ALDH1A1 (0.36) | USP2INMTCYP3A4CYP2D6CYP2C19 | |
| SCHEMBL16233137 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107241-A1 | SALEN COMPLEXES WITH DIANIONIC COUNTERIONS | NOVOMER, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-9403861-B2 | Salen complexes with dianionic counterions | NOVOMER, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-20140336354-A1 | SALEN COMPLEXES WITH DIANIONIC COUNTERIONS | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107241-A1 | SALEN COMPLEXES WITH DIANIONIC COUNTERIONS | NCLN, POLN, NCL | HRH4 4279/4885HRH2 4661/4885HRH3 3502/4885 |
| US-20140336354-A1 | SALEN COMPLEXES WITH DIANIONIC COUNTERIONS | NCLN, POLN, NCL | HRH4 4279/4885HRH2 4661/4885HRH3 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.